Valiant Laboratories Limited (VALIANTLAB) fundamentals
Valiant Laboratories Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as VALIANTLAB (ISIN INE0JWS01017). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Valiant Laboratories Limited does
Valiant Laboratories Limited is an India-based pharmaceutical ingredient manufacturing company. The Company is focused on manufacturing a Paracetamol active pharmaceutical ingredient (API)/bulk drug. It has several applications in the treatment of conditions such as headache, muscle ache, arthritis, backache, toothache, cold and fever. It is also used in the management of severe pain such as post-surgical and cancer pain. It operates a single-location manufacturing facility on the Tarapur industrial estate.
Valuation and market data
| Last close | ₹124.80 |
|---|---|
| Market capitalisation | ₹538 crore |
| Enterprise value | ₹640 crore |
| P/E (TTM) | 0.00 |
| Price to book | 2.30 |
| Price to sales (TTM) | 1.75 |
| Book value per share | ₹54.32 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Oct 06 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹240 crore | ₹1 crore | ₹-3 crore | 0.00 |
| Mar 2025 | ₹139 crore | ₹-2 crore | ₹-2 crore | -0.51 |
| Mar 2024 | ₹192 crore | ₹-1 crore | ₹0 crore | 0.13 |
| Mar 2023 | ₹339 crore | ₹38 crore | ₹29 crore | 8.91 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 74.9% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 25.1% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.